We highlight emerging uses of artificial intelligence (AI) in the field of theranostics, focusing on its significant potential to enable routine and reliable personalization of radiopharmaceutical therapies (RPTs). Personalized RPTs require patient-specific dosimetry calculations accompanying therapy. Additionally we discuss the potential to exploit biological information from diagnostic and therapeutic molecular images to derive biomarkers for absorbed dose and outcome prediction; toward personalization of therapies. We try to motivate the nuclear medicine community to expand and align efforts into making routine and reliable personalization of RPTs a reality.
Keywords: Artificial intelligence; Dosimetry; Outcome prediction; Quantitative imaging; Radiopharmaceutical therapies; Registration; Segmentation; Theranostics.
Copyright © 2021 Elsevier Inc. All rights reserved.